MedTrace Logo

Use of Blood and Plasma in Norwegian Physician-staffed Helicopter Emergency Medical System

NCT02784951 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2022-01-10

No results posted yet for this study

Summary

The main objective of this study is to evaluate the use of RBC, FDP, WB in the treatment of exsanguinating patients by physician-staffed emergency medical services in Norway, with focus on prehospital transfusion complications and safety.

Conditions

  • Hemorrhagic Shock

Interventions

DRUG

Red blood cells (0Rh D-neg)

Fresh produced RBC

DRUG

Whole blood (O Rh D-neg K-neg)

Fresh produced WB

DRUG

Freeze dried plasma (LyoPlas)

(LyoPlas N-w (German Red Cross)

Sponsors & Collaborators

  • Sykehuset Innlandet HF

    collaborator OTHER

  • Oslo University Hospital

    collaborator OTHER

  • Sorlandet Hospital HF

    collaborator OTHER_GOV

  • St. Olavs Hospital

    collaborator OTHER

  • Helse Forde

    collaborator OTHER

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • University Hospital of North Norway

    collaborator OTHER

  • Vestre Viken Hospital Trust

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Hanne Klausen, MD · Medical Director, Kirurgisk Serviceklinikk, Haukeland Universitetssykehus

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784951 on ClinicalTrials.gov